JAX has partnered with more than 20 cancer clinics to provide access to a wider range of patient-derived xenograft (PDX) cancer models at earlier passage numbers than any other PDX collection available today.
JAX PDX Resource: Development Process
More than 450 unique PDX oncology models from both treatment naive and resistant patients have been established in the highly immunodeficient NSG™ (005557) mouse strain. NSG™ mice engraft primary human tumors that, after low passage, retain the genetic and phenotypic heterogeneity typically seen in human cancers, offering a distinct advantage over other PDX hosts. This preclinical platform can predict the effectiveness of novel therapeutics to treat patients with cancer. We can conduct preclinical efficacy testing with customer-provided compounds at JAX using any of our PDX cancer models or ship PDX tumor-bearing mice to your facility.
PDX Live™ tumor models
Our collection of readily available, off-the-shelf PDX tumor-engrafted cohorts can help you put mice on study sooner, allowing rapid study turnaround and faster decision-making.
See our inventory of PDX Live™ tumor-bearing mice
A complete PDX cancer resource
These tumors types are available for engraftment in NSG™ mice for shipment of tumor-bearing mice to your facility or for execution of efficacy studies performed in our facility by our oncology scientists:
- Acute myeloid leukemia (AML) models
- Bladder cancer
- Breast cancer
- Lung cancer
- Ovarian cancer
- Pancreatic cancer